The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
Open accessAbstract
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS. RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone. CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treatment with donepezil was associated with cognitive benefits that exceeded the minimum clinically important difference and with significant functional benefits over the course of 12 months. (Funded by the U.K. Medical Research Council and the U.K. Alzheimer's Society; Current Controlled Trials number, ISRCTN49545035.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new look at the statistical model identification
Akaike, H. (1974) · IEEE Transactions on Automatic Control · doi:10.1109/tac.1974.1100705 · Cited by 51,879
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700
ANew Look at the Statistical Model Identification
AKAlKE, H. (2011) · Cited by 4,177
The Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, S. C., Lamping, D. L., Banerjee, S., Harwood, R., Foley, B., Smith, P. B., Cook, J., Murray, J., Prince, M. J., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 651
Research works printed but not linked: 3
- Areosa SA, 2005, Cochrane Database Syst Rev, 3, CD003154
- Smith SC, 2005, Health Technol Assess, 9, 1
- 10.1097/00005650-200305000-00004 · DOI
Cited by
Sorted by citations
Items 301–400 of 787
Li, J., Chen, L., Liu, S., Sun, Y., Zhen, L., Zhu, Z., Wang, G., & Li, X. (2023) · Cells · doi:10.3390/cells12192348 · Cited by 18
Satarker, S., Gurram, P. C., Nassar, A., Manandhar, S., Vibhavari, R. J. A., Yarlagadda, D. L., Mudgal, J., Lewis, S. A., Arora, D. S., & Nampoothiri, M. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03844-4 · Cited by 16
Fisher, T., Schwartz, A., Greenspan, H. N., & Heinrich, T. W. (2016) · International Journal of Psychiatry in Medicine · doi:10.1177/0091217416636579 · Cited by 19
Treatment of Alzheimer's Disease: Classical Therapeutic Approach
Bajić, V., Sudar-Milovanovic, E. M., Spremo‐Potparević, B., Živković, L., Milicevic, Z., Stanimirović, J., Bogdanović, N., & Isenović, E. R. (2015) · Current Pharmaceutical Analysis · doi:10.2174/1573412911666150611184740 · Cited by 16
Gene Editing and Alzheimer's Disease: Is There Light at the End of the Tunnel?
Stepanichev, M. Y. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.00004 · Cited by 17
Ju, C., Wong, I. C. K., Lau, W. C. Y., Man, K. K. C., Brauer, R., Ma, T., Alsharif, A. A., Alwafi, H. H., Lau, K. K., Chan, E. W., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15053 · Cited by 16
Grossberg, G. T., Farlow, M. R., Meng, X., & Velting, D. M. (2015) · Current Alzheimer Research · doi:10.2174/1567205011666141218122835 · Cited by 16
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans
Ling, I., Golde, T. E., Galasko, D. R., & Koo, E. H. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0137-y · Cited by 16
Management of Behavioral and Psychological Symptoms of Dementia
Cankurtaran, E. Ş. (2014) · Nöro Psikiyatri Arşivi · doi:10.5152/npa.2014.7405 · Cited by 20
Nagata, T., Shinagawa, S., Nakajima, S., Mimura, M., & Shigeta, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180304 · Cited by 16
Clinical Investigation of Tyrosinase Inhibitors: Past, Present, and Future
Wang, Y. Y., Jiang, R., Xiong, B., Zhu, J., Sang, J., Li, H., Chen, C., Xu, Z., Zhang, W., Chen, Y., et al. (2025) · Drug Development Research · doi:10.1002/ddr.70113 · Cited by 19
Tsanov, M. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.916499 · Cited by 15
Havreng‐Théry, C., Oquendo, B., Zolnowski‐Kolp, V., Krolak‐Salmon, P., Bertin‐Hugault, F., Lafuente‐Lafuente, C., & Belmin, J. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01481-0 · Cited by 16
Photoredox‐Catalyzed [3+2] annulation of Aromatic Amides with Olefins via Iminium Intermediates
Tang, Z., Yao, Z., Yu, Y., Huang, J., Ma, X., Zhao, X., Chang, Z., & Zhao, D. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202412152 · Cited by 15
Pfeil, A. M., Kressig, R. W., & Szucs, T. D. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13676 · Cited by 15
Chang, Y.-H., Chen, S., Lee, S.-Y., Chen, P. S., Wang, T., Lee, I. H., Chen, K. C., Yang, Y. K., Hong, J., & Lu, R. (2015) · Scientific Reports · doi:10.1038/srep09708 · Cited by 16
Emerging amyloid and tau targeting treatments for Alzheimer’s disease
Khan, A., Corbett, A., & Ballard, C. G. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1326819 · Cited by 16
Naughton, M. J., Case, L. D., Peiffer, A. M., Chan, M. D., Stieber, V. W., Moore, D., Falchuk, S. C., Piephoff, J. V., Edenfield, W. J., Giguere, J. K., et al. (2017) · Neuro-Oncology Practice · doi:10.1093/nop/npx016 · Cited by 15
Hong, Y. J., Choi, S. H., Jeong, J. H., Park, K. W., & Na, H. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180159 · Cited by 15
Behavioral management in the person with dementia
Morley, J. E. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0406-4 · Cited by 14
Drug therapies in older adults (part 1)
Mukhtar, O., & Jackson, S. H. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-1-47 · Cited by 14
Hapca, S. M., Burton, J. K., Cvoro, V., Reynish, E. L., & Donnan, P. T. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.07.011 · Cited by 14
Alzheimer's disease medication and outcomes of hospitalisation among patients with dementia
Möllers, T., Perna, L., Stocker, H. R., Ihle, P., Schübert, I., Schöttker, B., Frölich, L., Bauer, J. M., & Brenner, H. (2019) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796019000702 · Cited by 15
Sommerlad, A., Werbeloff, N., Perera, G., Smith, T., Costello, H., Mueller, C., Kormilitzin, A., Broadbent, M., Nevado‐Holgado, A., Lovestone, S., et al. (2022) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5625 · Cited by 14
Möllers, T., Stocker, H. R., Perna, L., Rujescu, D., Holleczek, B., Schöttker, B., & Brenner, H. (2022) · Age and Ageing · doi:10.1093/ageing/afac113 · Cited by 14
Targeted studies on the interaction of nicotine and morin molecules with amyloid β-protein
Boopathi, S., & Kolandaivel, P. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2109-8 · Cited by 15
Prescription patterns of antidementives in a high income country: A pharmacoepidemiologic study
Wurm, R., Stamm, T., Reichardt, B., Schwarz, F. K., Parvizi, T., Silvaieh, S., König, T., Çetin, H., & Stögmann, E. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12014 · Cited by 14
Simulated presence therapy for dementia.
Abraha, I., Rimland, J., Lozano-Montoya, I., Dell’Aquila, G., Vélez-Díaz-Pallarés, M., Trotta, F., Cruz-Jentoft, A., & Cherubini, A. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011882.pub3 · Cited by 40
Nicotinic Acetylcholine Receptors Contribute to Learning-induced Metaplasticity in the Hippocampus
Becker, B., Klein, E. M., Striepens, N., Mihov, Y., Schlaepfer, T. E., Reul, J., Goossens, L., Schruers, K. R. J., Kendrick, K. M., & Hurlemann, R. (2013) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_00383 · Cited by 14
Discontinuing Donepezil or Starting Memantine for Alzheimer's Disease
Schneider, L. S. (2012) · New England Journal of Medicine · doi:10.1056/nejme1200429 · Cited by 14
Zhao, J., Li, Z., Zhang, R., Yu, H., & Zhang, L. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-04771-8 · Cited by 16
Khedraoui, M., Guerguer, F. Z., Karim, E. M., Errougui, A., & Chtita, S. (2025) · Current Pharmaceutical Analysis · doi:10.1016/j.cpan.2025.03.005 · Cited by 14
Pharmacological Treatment of Dementia
Hahn, S. J., & Paik, N. (2015) · Brain & Neurorehabilitation · doi:10.12786/bn.2015.8.1.19 · Cited by 13
Eckel, B. A., Ohl, F., Starker, L., Rammes, G., Bogdanski, R., Kochs, E. F., & Blobner, M. (2012) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835b824b · Cited by 13
Ritchie, C. W., & Zhinchin, G. (2013) · International Psychogeriatrics · doi:10.1017/s1041610212002414 · Cited by 13
Long-term effects of Alzheimer's disease treatment
Wimo, A. B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00302-6 · Cited by 13
Corbett, A., & Ballard, C. G. (2014) · BMJ Evidence-Based Medicine · doi:10.1136/eb-2014-101741 · Cited by 13
Verbandt, S., Cammue, B. P. A., & Thevissen, K. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.06.003 · Cited by 13
Effects of donepezil on liver and kidney functions for the treatment of Alzheimer’s disease
Erbayraktar, Z., EVLİCE, A. T., Yener, G., & Ulusu, N. N. (2017) · Journal of Integrative Neuroscience · doi:10.3233/jin-170020 · Cited by 13
Dementia and Cognitive Impairment
Rossor, M. N., Collinge, J., Fox, N. C., Mead, S., Mummery, C. J., Rohrer, J. D., Schott, J. M., & Warren, J. D. (2016) · Wiley eBooks · doi:10.1002/9781118486160.ch8 · Cited by 14
Hajihosseini, S., Zakavi, S. A., Farrokhi, Z., Amanzadeh, M., Panahi, P., Mahram, M., Eftekhari, N., Noroozi, M., Ebrahimi, M. J., Alizadeh, A., et al. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.016 · Cited by 14
Translating Alzheimer’s Disease Mechanisms into Therapeutic Opportunities
Li, J., Wang, L., Zhang, X., Shi, J., Zhu, Y. Z., Wang, H., Zhu, X., Zhu, Q., & Luo, J. (2025) · Biomolecules · doi:10.3390/biom15091290 · Cited by 13
Identification of anti-prion drugs and targets using toxicity-based assays
Mercer, R. C. C., & Harris, D. A. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.12.005 · Cited by 11
Wang, L., Gao, Y., Hu, Y., Li, R., Han, Z., Geng, Y., Xia, Z., Liu, L., Du, W., & Zhang, H. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s78025 · Cited by 13
Yan, J., & Bading, H. (2023) · Pharmaceuticals · doi:10.3390/ph16081085 · Cited by 12
The Clinical Problem of Neuropsychiatric Signs and Symptoms in Dementia
Burke, A. D., Hall, G. R., & Tariot, P. N. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000429177.14354.83 · Cited by 12
Nakamura, K., Ohkawa, H., Ando, M., Ogura, Y., Funabiki, S., Kume, A., Urano, K., Osada, T., Yamamura, K., & Watanabe, N. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s69750 · Cited by 12
Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer’s Disease
Tian, J., Shi, J., Ni, J., Wei, M., Zhang, X., Chen, K., & Wang, Y.-Y. (2019) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-019-3066-y · Cited by 11
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 12
Study on the role and mechanism of Tan IIA in Alzheimer’s disease based on CREB-BDNF-TrkB pathway
Xiang, X., Xia, S., Zeng, Y., Wang, L., Yu, J., Liang, M., & Zhou, Y. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137769 · Cited by 12
Zarneshan, S. N., Arkan, E., Kiani, A., Hosseini, S. Z., Abbaszadeh, F., & Fakhri, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03696-2 · Cited by 12
Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon
Malik, B. H., Hamid, P., Khan, S., Gupta, D., & Islam, M. (2019) · Cureus · doi:10.7759/cureus.6451 · Cited by 11
Rausch, C., & Hoffmann, F. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02859-3 · Cited by 8
Jiang, F., Ren, J., Gao, Y., Wang, J., Zhao, Y., & Dai, F. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.11.024 · Cited by 11
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
Painuli, S., Semwal, P., Zam, W., Taheri, Y., Ezzat, S. M., Zuo, P., Li, L., Kumar, D., Sharifi‐Rad, J., & Martins, N. A. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220428112541 · Cited by 11
Świetlik, D., Białowas, J., Kusiak, A., & Krasny, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050546 · Cited by 11
Zhang, Y., Zhang, Y., Jiang, Z., Xu, M., & Qing, K. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1269359 · Cited by 11
Hendrix, S. B., Ellison, N., Stanworth, S., Otcheretko, V., & Tariot, P. N. (2015) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2015.66 · Cited by 11
Dolci, G. A. M., Damanti, S., Scortichini, V., Galli, A., Rossi, P. D., Abbate, C., Arosio, B., Mari, D., Arighi, A., Fumagalli, G., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00203 · Cited by 12
Past and Future of Drug Treatments for Alzheimer's Disease
Kim, S. Y. (2018) · 신경정신의학 · doi:10.4306/jknpa.2018.57.1.30 · Cited by 11
Cho, E., Cai, M., Kwon, H., Jeon, J., Moon, M., Jun, M., Lee, Y. C., Yi, J. H., Ryu, J. H., & Kim, D. H. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110698 · Cited by 11
Baek, I., Kim, T., Seo, J., Lee, K.-W., Lee, Y. A., Cho, J., Gwag, B. J., & Han, P. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.31 · Cited by 11
Palafox, M. A., Posada-Moreno, P., Ortuño‐Soriano, I., del Cerro, J. L. P., Martínez-Rincón, C., Rodrı́guez-Martı́nez, D., & Pacheco-Cuevas, L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-803959-5.50008-8 · Cited by 11
Les aspects génétiques de la maladie d’Alzheimer (Revue)
Kadmiri, N. E., Hamzi, K., Moutawakil, B. E., Slassi, I., & Nadifi, S. (2013) · Pathologie Biologie · doi:10.1016/j.patbio.2013.04.001 · Cited by 20
Pharmacotherapeutic combinations for the treatment of Alzheimer’s disease.
Nagata, T., Shinagawa, S., Nakajima, S., Noda, Y., & Mimura, M. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2042514 · Cited by 11
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Simulated presence therapy for dementia: a systematic review protocol
Abraha, I., Rimland, J., Lozano-Montoya, I., Dell’Aquila, G., Vélez-Díaz-Pallarés, M., Trotta, F., & Cherubini, A. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-011007 · Cited by 10
Neurokognitive Störungen im Alter
Pantel, J. (2016) · Der Internist · doi:10.1007/s00108-016-0097-8 · Cited by 9
Nagata, T., Nakajima, S., Shinagawa, S., Plitman, E., Nakayama, K., Graff‐Guerrero, A., & Mimura, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170412 · Cited by 10
Alzheimer Disease and Other Dementias
Whalen, R. M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0779-3_25-1 · Cited by 10
Alzheimer’s Treatment: Real-World Physician Behavior Across Countries
Podhorná, J., Winter, N., Zoebelein, H., & Perkins, T. (2020) · Advances in Therapy · doi:10.1007/s12325-019-01213-z · Cited by 9
Psychological Problem Diagnosis and Management in the Geriatric Age Group
Thakur, U., & Varma, A. R. (2023) · Cureus · doi:10.7759/cureus.38203 · Cited by 13
Zhao, M., Yimiao, L., Wang, H., Yu, C., Li-na, M., Hui, P., & Hao, L. I. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230404.006 · Cited by 10
Zhu, X., Lv, Y., Fan, M., Guo, J., Zhang, Y., Gao, B., Zhang, C., & Xie, Y. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106817 · Cited by 9
Kotting, P. M., Beicher, K., McKeith, I. G., & Rossor, M. N. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt126 · Cited by 9
Neuroprotective strategies for NMDAR-mediated excitotoxicity in Huntington’s Disease
Girling, K., & Wang, Y. T. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1425-z · Cited by 9
Vassilis Cutsuridis, A., & Moustafa, A. A. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2016.12.001 · Cited by 9
Ishiguro, S., Shinada, T., Wu, Z., Karimazawa, M., UCHIDATE, M., Nishimura, E., Yasuno, Y., Ebata, M., Sillapakong, P., Ishiguro, H., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0245235 · Cited by 9
McCloskey, B., Hughes, C. M., & Parsons, C. (2018) · Palliative Medicine · doi:10.1177/0269216318757163 · Cited by 9
Saribudak, A., Subick, A. A., Kim, N. H., Rutta, J. A., & Uyar, M. Ü. (2018) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2018.2870363 · Cited by 8
Zhao, L., Cheng, X., & Zhong, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00450 · Cited by 9
Cao, Y., Liang, Q., Yu, W., Li, T., Mao, S., & Han, G. (2020) · Journal of International Medical Research · doi:10.1177/0300060520902895 · Cited by 9
Kim, H.-J., Shim, Y., Han, H. J., Kim, B. C., Park, K. H., Moon, S. Y., Choi, S. H., Yang, D. W., Yoon, B., Kim, E., et al. (2023) · Neurology and Therapy · doi:10.1007/s40120-023-00494-5 · Cited by 9
Toward Prevention and Reduction of Alzheimer’s Disease
González-Madrid, A., Calfío, C., González, A., Lüttges, V., & Maccioni, R. B. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230454 · Cited by 8
Reshma, A., Subramanian, A., Kumarasamy, V., Tamilanban, T., Sekar, M., Gan, S. H., Subramaniyan, V., Wong, L. S., Rani, N. N. I. M., & Wu, Y. S. (2024) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2024e13587 · Cited by 8
Du, Y., Cao, J., Gao, C., He, K., & Wang, S. (2025) · Pain and Therapy · doi:10.1007/s40122-024-00702-6 · Cited by 9
Novel Copper Chelators Enhance Spatial Memory and Biochemical Outcomes in Alzheimer’s Disease Model
Camargo, M. L. M., Farias, A. B., Bertazzo, G. B., Gomes, R. N., Gomes, K. S., Bosquetti, L. M., Takada, S. H., Braga, F. C., Augusto, C. C., Batista, B. L., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00291 · Cited by 8
Oh, S.-T., Han, K., Choi, W., & Park, J. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.010 · Cited by 7
Herr, M., Ankri, J., Diard, C., & Hiance‐Delahaye, A. (2021) · Drugs & Aging · doi:10.1007/s40266-020-00817-3 · Cited by 8
Riluzole restores memory and brain energy metabolism in AβPP-PS1 mouse model of Alzheimer's disease
Saba, K., & Patel, A. B. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.04.051 · Cited by 8
Disease-modifying vs symptomatic treatments: Splitting over lumping
Duque, K. R., Vizcarra, J. A., Hill, E. J., & Espay, A. J. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00020-5 · Cited by 9
Robinson, M. J., Newbury, S., Singh, K., Leonenko, Z., & Beazely, M. A. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230753 · Cited by 8
Conde‐Sala, J. L., Garre‐Olmo, J., Franch, J. V., Reglà, J. L., Garriga, O. T., Gallego, M. L., Hernández-Ferràndiz, M., Nierga, I. P., & Pousa, S. L. (2013) · Revista de Neurología · doi:10.33588/rn.5612.2013118 · Cited by 8
Probandenverfügung in der Arzneimittelforschung
Haupt, M., Jessen, F., & Fangerau, H. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0392-1 · Cited by 8
Disalvo, D., Luckett, T., Luscombe, G. M., Bennett, A. A., Davidson, P. M., Chenoweth, L., Mitchell, G. K., Pond, D. C., Phillips, J. L., Beattie, E., et al. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0070 · Cited by 8
Room for improvement in reporting of trials discontinuing long-term medication: a systematic review
Dirven, T. L. A., Turner, C. M., Thio, S. L., Blom, J. W., Muth, C., & van Driel, M. (2019) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2019.11.013 · Cited by 8
Kim, D. H., Li, X., Bian, S., Wei, L., & Sun, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.34745 · Cited by 8
Early-Onset Alzheimer Disease (EOAD) With Aphasia: A Case Report
Borges, M. K., Lopes, T. N., Biella, M. M., de Siqueira, A. S. S., Mauer, S., & Aprahamian, I. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00469 · Cited by 8
Knopman, D. S. (2012) · Neurology Clinical Practice · doi:10.1212/cpj.0b013e318278bebd · Cited by 8
Enfermedad de Alzheimer: nuevas estrategias terapéuticas
Villegas, S. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.05.023 · Cited by 10
Metadata
- Authors
- Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., Hughes, A., Jacoby, R., Jones, R., Jones, R., McKeith, I., Macharouthu, A., O'Brien, J., Passmore, P., Sheehan, B., Juszczak, E., Katona, C., Hills, R., Knapp, M., Ballard, C., Brown, R., Banerjee, S., Onions, C., Griffin, M., Adams, J., Gray, R., Johnson, T., Bentham, P., & Phillips, P.
- Affiliations
- King's College London (GB)
- Churchill Hospital (GB)
- University of Leicester (GB)
- Whiston Hospital (GB)
- Newcastle University (GB)
- University of Manchester (GB)
- Fulbourn Hospital (GB)
- University of Oxford (GB)
- Inverclyde Royal Hospital (GB)
- Crichton Royal Hospital (GB)
- Queen's University Belfast (GB)
- University of Warwick (GB)
- University College London (GB)
- University of Wales (GB)
- Avon and Wiltshire Mental Health Partnership NHS Trust (GB)
- University of Cambridge (GB)
- Queen Elizabeth Hospital Birmingham (GB)
- ORCID
- Howard, Robert
- McShane, Rupert
- Ritchie, Craig
- Baldwin, Ashley
- Barber, Robert
- Burns, Alistair
- Dening, Tom
- Findlay, David
- Holmes, Clive
- Jones, Roy
- McKeith, Ian
- Macharouthu, Ajay
- O'Brien, John
- Passmore, Peter
- Sheehan, Bart
- Juszczak, Edmund
- Katona, Cornelius
- Hills, Robert
- Knapp, Martin
- Ballard, Clive
- Brown, Richard
- Banerjee, Sube
- Gray, Richard
- Johnson, Tony
- Bentham, Peter
- Phillips, Patrick
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 893-903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151585937
- Cited by
- 782
- References
- 31
- Citations by year
- 2026: 43 · 2025: 49 · 2024: 44 · 2023: 58 · 2022: 51 · 2021: 48 · 2020: 45 · 2019: 58 · 2018: 47 · 2017: 55 · 2016: 54 · 2015: 54 · 2014: 59 · 2013: 74 · 2012: 40
- FWCI
- 52.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion, other-oa)
- Warwick Research Archive Portal (University of Warwick) (acceptedVersion)
- Leicester Research Archive (University of Leicester) (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Alzheimer's Society
- King's College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- Alzheimer's disease, donepezil, memantine, cholinesterase inhibitors, NMDA receptor antagonists, combination therapy, cognitive function, activities of daily living, functional disability, treatment continuation, community-dwelling patients, minimal clinically important difference, treatment discontinuation
- MeSH terms
- Donepezil, Aged, Aged, 80 and over, Alzheimer Disease, Cholinesterase Inhibitors, Double-Blind Method, Drug Synergism, Drug Therapy, Combination, Female, Humans, Indans, Male, Memantine, Patient Dropouts, Piperidines, Psychological Tests, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Excitatory Amino Acid Antagonists, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
